Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P49770
UPID:
EI2BB_HUMAN
Alternative names:
S20I15; S20III15; eIF-2B GDP-GTP exchange factor subunit beta
Alternative UPACC:
P49770; O43201
Background:
The Translation initiation factor eIF-2B subunit beta, known by alternative names such as S20I15, S20III15, and eIF-2B GDP-GTP exchange factor subunit beta, plays a crucial role in protein synthesis. It catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP, a key step in the initiation of translation.
Therapeutic significance:
This protein is implicated in Leukoencephalopathy with vanishing white matter 2, a severe brain disease with symptoms ranging from cerebellar ataxia to cognitive deficits. Understanding the role of Translation initiation factor eIF-2B subunit beta could open doors to potential therapeutic strategies for this debilitating condition.